Kuros Biosciences Ltd.

Regulatory Filings • Jun 4, 2010

News Details

Corporate | 4 June 2010 07:00

Cytos Biotechnology Ltd: CYT003-QbG10 phase IIb data presented at EAACI 2010 in London, UK

Cytos Biotechnology AG / Miscellaneous

04.06.2010 07:00

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Cytos Biotechnology Ltd (SIX:CYTN) is pleased to inform you about two
presentations at the 29th Congress of the European Academy of Allergy and
Clinical Immunology in London, UK from June 5-9, 2010.

Prof. Klimek, the principal investigator of the study, will present
'Treatment with CYT003-QbG10, an allergen-free immunomodulator, reduces
allergic symptoms in patients with rhinoconjunctivitis due to house dust
mite allergy' on Sunday, June 6, 2010, 10.30 am-12.00 pm.

Dr. Bachmann, CSO of Cyots Biotechnology, will present 'Bacteriophage
coupled Fel d1 a novel immunotherapy agent for cat allergy' on Tuesday,
June 8, 2010 at 10.30 am.

Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner@cytos.com
Website: www.cytos.com

04.06.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open
Market in Frankfurt; Foreign Exchange(s) SIX

End of News DGAP News-Service

---